
Appendix 1. Predicted and actual costs breakdown

	Budgeted Costs			Actual Costs		
	At Year-end 2020 240 Patient Scenario			Project end		
				258 Patients E	nrolled	
	Per Patient	Total		Per Patient	Total	
	Amounts in	Amounts in €	Percents	Amounts in €	Amounts in €	€ Percents
Medication						
Primary treatment Medication	34	82,800	17.9%	357	92,026	19.2%
Retreatment Medication	5	9 14,040	3.0%	67	17,323	3.6%
Total medication	€ 403.50	€ 96,840.00	21.0%	€ 424	€ 109,349	22.8%
Diagnostic Costs						
Viral Load Tests						
RNA Viral Load Lab Costs (S -4)	4-	10,448	2.3%	63	17,015	3.4%
RNA Viral Load Lab Costs (S 24)	1	3,840	0.8%	03	17,013	3.4/0
RNA Viral Load GeneXpert Cartridges	50	11,973	2.6%	63	16,129	3.4%
Total Viral Load per Enrolled Patient	€ 109	€ 26,261	5.7%	€ 125	€ 33,143	6.7%
Other Diagnostics						
ELISA	1			7	1,745	0.4%
Basic Labs	4.	2 10,077				
Tests for Complications (per enrolled)	1	3,155	0.7%	60	15,514	3.2%
Retreatment Diagnostics	1	, -				
Total Other Diagnostis		€ 20,467	4.4%	€ 67	€ 17,260	3.6%
Total Medication & Diagnostic Costs	€ 598	143,568	31.1%	€ 616	€ 159,752	33.1%
Cameroonian Medical Support Costs						
Salaries and Site Support						
Blood Bank Teams	16	39,039	8.4%	78	20,030	4.2%
Clinical Treatment Teams	22	53,543	11.6%	148	38,268	8.0%
Project Implementation Team	47	1 112,963	24.4%	541	139,513	29.1%
Total Cameroonian Salaries and Site Support	€ 856	€ 205,545	44.5%	€ 767	€ 197,812	41.3%
Other Cameronian Costs (logistical & admin)	173	8 42,661	9.2%	155	39,889	8.3%
Total Cameroonian Medical Support Costs	€ 1,034	€ 248,206	53.7%	€ 921	€ 237,700	49.6%
Offshore Project Support Costs						
Outcome Verification (ANRS)	7:	1 17,064	3.7%	80	20,652	4.3%
Facility Administration (GLAS)	10-	4 25,000	5.4%	116	30,000	6.3%
Financing Costs (Fees + Interest)	58	13,838	3.0%	75	19,450	4.1%
Electronic CRF	60	14,380	3.1%	49	12,760	2.7%
Total Offshore Project Support Costs	€ 293	€ 70,282	15.2%	€ 321	€ 82,863	17.3%
Total Per Patient Costs	€ 1,925	€ 462,055	100.0%	€ 1,858	€ 480,315	100.0%
Finding						
Funding Patient contribution	6	9 16,463	3%	76	19,512	4%
Outcome payments	1,65			1,542	397,800	81%
Additional COVID-19 funding	30			281	72,500	15%
Total funding available	€ 2,02 8	,		€ 1,898		100%
Total fallang available	, and the second		100/6			100/0
Contingency	€ 103	€ 24,709	5.35%	€ 37	€ 9,497	1.98%

Notes. The actual total per patient cost (€1,858) is lower than the modelled total per patient cost (€1,925) because of efficiencies of scale generated through more patients having been included in treatment (n=258) than was estimated in this prediction model (n=240). For this same reason, actual total program costs (€480,315) were higher than modelled total costs (€462,055). The higher costs could be accommodated due to the 5% funding contingency allowed for in the model. During the course of the program, actual costs were regularly checked against expected expenditure to ensure that the program did not exceed the budget. At the end of the program, available funding exceeded actual costs by around €9,500, demonstrating that the applied financial model functioned accurately.

Appendix 2. Framework for evaluating Development Impact Bonds, based on proposal DFID



Appendix 3. Interviewed stakeholders

Stakeholder	Role	Number of participants	
Joep Lange Institute	Investor	2	
Centre Pasteur Cameroon	Service provider	2	
Laboratoire de Recherche sur les Hepatites	Service provider	5	
virales et la Communication en Sante			
ANRS	Outcome evaluator	1	
Legal department PharmAccess Foundation	Intermediary	1	
PharmAccess Foundation	Intermediary	3	
Medical advisor and country expert	External advisor	1	
Achmea Foundation	Outcome payer	3	
Global Loan Agency Services (GLAS)	Intermediary	1	
Health economist expert	External advisor	1	
Celle de PBF, Cameroonian government	Contextual actor	1	
HEREG	External advisor	1	
Total	11 interviews	22 persons	